Immunohistochemical expression and prognostic significance of CCND3, MCM2 and MCM7 in Hodgkin lymhoma

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3585-3594

  Marnerides, Andreas ^a,b   Vassilakopoulos, Theodoros P ^a   Boltetsou, Evmorfia ^a   Levidou, Georgia ^a   Angelopoulou, Maria K ^a   Thymara, Irene ^a   Kyrtsonis, Marie Christine ^a   Pappi, Vassiliki ^a   Tsopra, Olga ^a   Panayiotidis, Panayiotis ^a   Pangalis, Gerassimos A ^a   Beris, Photis ^a   Patsouris, Efstratios ^a   Korkolopoulou, Penelope ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CCND3; Cyclin D3; Hodgkin lymphoma; MCMs; Minichromosome maintenance proteins; Survival

Indexed keywords

ANTHRACYCLINE; CHLORAMBUCIL; CHLORMETHINE; CYCLIN D3; KI 67 ANTIGEN; MINICHROMOSOME MAINTENANCE PROTEIN 2; MINICHROMOSOME MAINTENANCE PROTEIN 7; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE-RICH CLASSICAL HODGKIN LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN D3; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NUCLEAR PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 80054772207     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E and Loeffler M: German Hodgkin's Lymphoma Study Group: Standard and increased - dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348: 2386-2395, 2003. (Pubitemid 36682817)
2. Hasenclever D and Diehl V: A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339: 1506-1514, 1998.
3. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Barbounis A, Grigorakis V, Karkantaris C, Anargyrou K, Chatziioannou M, Rombos J, Boussiotis VA, Vaiopoulos G, Kittas C and Pangalis GA: Prognostic factors in advanced stage Hodgkin's lymphoma: the significance of the number of involved anatomic sites. Eur J Haematol 67: 279-288, 2001. (Pubitemid 34135440)
4. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Kontopidou FN, Dimopoulou MN, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Karkantaris C, Anargyrou K, Boutsis DE, Variamis E, Michalopoulos T, Boussiotis VA, Panayiotidis P, Papavassiliou C and Pangalis GA: Combination chemotherapy plus low-dose involved-field radiotherapy for early clinical stage Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 59: 765-781, 2004. (Pubitemid 38748742)
5. INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood 103: 2351-2357, 2004.
6. García JF, Camacho FI, Morente M, Fraga M, Montalbán C, Alvaro T, Bellas C, Castaño A, Díez A, Flores T, Martin C, Martinez MA, Mazorra F, Menárguez J, Mestre MJ, Mollejo M, Sáez AI, Sánchez L and Piris MA; Spanish Hodgkin Lymphoma Study Group: Hodgkin and Reed-Sternberg cells harbor alterations in the major suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 101: 681-689, 2003. (Pubitemid 36077593)
7. Tzankov A, Zimpfer A, Lugli A, Krugmann J, Went P, Schraml P, Maurer R, Ascani S, Pileri S, Geley S and Dirnhofer S: High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin El. J Pathol 199: 201-207, 2003. (Pubitemid 36176026)
8. Rassidakis GZ, Medeiros LJ, Vassilakopoulos TP, Viviani S, Bonfante V, Nadali G, Herling M, Angelopoulou MK, Giardini R, Chilosi M, Kittas C, McDonnell TJ, Bonadonna G, Gianni AM, Pizzolo G, Pangalis GA, Cabanillas F and Sarris AH: BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regiments. Blood 100: 3935-3941, 2002. (Pubitemid 35396858)
9. Bai M, Tsanou E, Agnantis NJ, Kamina S, Grepi C, Stefanaki K, Rontogianni D, Galani V and Kanavaros P: Proliferation profile of classical Hodgkin's lymphomas. Increased expression of the protein cyclin D2 in Hodgkin's and Reed-Sternberg cells. Mod Pathol 17: 1338-1345, 2004. (Pubitemid 39472988)
10. 1 phase. Arch Iran Med 11: 532-538, 2008.
11. Sherr CJ and Roberts JM: Living with or without cyclins and cyclin-dependent kinases. Genes Dev 18: 2699-2711, 2004. (Pubitemid 39507762)
12. Stoeber K, Tlsty TD, Happerfield L, Thomas GA, Romanov S, Bobrow L, Williams ED and Williams GH: DNA replication licensing and human cell proliferation. J Cell Sci 114: 2027-2041, 2001. (Pubitemid 32586628)
13. Barkley LR, Hong HK, Kingsbury SR, James M, Stoeber K and Williams GH: CDC6 is a rate-limiting factor for proliferative capacity during HL60 cell differentiation. Exp Cell Res 313: 3789-3799, 2007. (Pubitemid 47464231)
14. Tachibana KE, Gonzalez MA and Coleman N: Cell-cycle-dependent regulation of DNA replication and its relevance to cancer pathology. J Pathol 205: 123-129, 2005. (Pubitemid 40227985)
15. Korkolopoulou P, Givalos N, Saetta A, Goudopoulou A, Gakiopoulou H, Thymara I, Thomas-Tsagli E and Patsouris E: Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators. Hum Pathol 36: 899-907, 2005. (Pubitemid 41187909)
16. Tzankov A, Zimpfer A, Went P, Maurer R, Pileri SA, Geley S and Dirnhofer S: Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. Mod Pathol 18: 90-96, 2005. (Pubitemid 40128100)
17. Gonzalez MA, Pinder SE, Callagy G, Vowler SL, Morris LS, Bird K, Bell JA, Laskey RA and Coleman N: Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 21: 4306-4313, 2003. (Pubitemid 46628462)
18. Hunt DP, Freeman A, Morris LS, Burnet NG, Bird K, Davies TW, Laskey RA and Coleman N: Early recurrence of benign meningioma correlates with expression of minichromosome maintenance-2 protein. Br J Neurosurg 16: 10-15, 2002. (Pubitemid 34246180)
19. Hashimoto K, Araki K, Osaki M, Nakamura H, Tomita K, Shimizu E and Ito H: MCM2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications. Pathobiology 71: 193-200, 2004. (Pubitemid 38969877)
20. Doussis-Anagnostopoulou IA, Vassilakopoulos TP, Thymara I, Korkolopoulou P, Angelopoulou MK, Siakantaris MP, Kokoris SI, Dimitriadou EM, Kalpadakis C, Matzouranis M, Kaklamanis L, Panayiotidis P, Kyrtsonis MC, Androulaki A, Patsouris E, Kittas C and Pangalis GA: Topoisomerase II alpha expression as an independent prognostic factor in Hodgkin's lymphoma. Clin Cancer Res 14: 1759-1766, 2008. (Pubitemid 351469461)
21. Sánchez-Aguilera A, Montalbán C, de la Cueva P, Sánchez-Verde L, Morente MM, García-Cosío M, García-Laraña J, Bellas C, Provencio M, Romagosa V, de Sevilla AF, Menárguez J, Sabin P, Mestre MJ, Méndez M, Fresno MF, Nicolás C, Piris MA and García JF; Spanish Hodgkin Lymphoma Study Group: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108: 662-668, 2006. (Pubitemid 44061368)
22. Sánchez-Espiridión B, Montalbán C, López A, Menárguez J, Sabín P, Ruiz-Marcellán C, Lopez A, Ramos R, Rodríguez J, Cánovas A, Camarero C, Canales M, Alves J, Arranz R, Acevedo A, Salar A, Serrano S, Bas A, Moraleda JM, Sánchez-Godoy P, Burgos F, Rayón C, Fresno MF, Laraña JG, García-Cosío M, Santonja C, López JL, Llanos M, Mollejo M, González-Carrero J, Marín A, Forteza J, García-Sanz R, Tomás JF, Morente MM, Piris MA and García JF; Spanish Hodgkin Lymphoma Study Group: A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood 116: 12-17, 2010.
23. Chetaille B, Bertucci F, Finetti P, Esterai B, Stamatoullas A, Picquenot JM, Copin MC, Morschhauser F, Casasnovas O, Petrella T, Molina T, Vekhoff A, Feugier P, Bouabdallah R, Birnbaum D, Olive D and Xerri L: Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 113: 2765-2775, 2009.
24. Vassilakopoulos TP and Pangalis GA: Biological prognostic factors in Hodgkin's lymphoma. Haema 7: 147-164, 2004. (Pubitemid 38470357)
25. Smolewski P, Niewiadomska H, Los E and Robak T: Spontaneous apoptosis of Reed-Sternberg and Hodgkin cells; clinical and pathological implications in patients with Hodgkin's disease. Int J Oncol 17: 603-609, 2000.
26. Stein H, Delsol G, Pileri S, Said J, Mann R, Poppema S, Jaffe ES and Swerdlow SH: Hodgkin lymphoma. In: Pathology and Genetics. Tumours of Haematopoietic and Lymphoid Tissues. WHO Classification of Tumours, Volume 3, third edition. Jaffe ES, Harris NL and Stein H, Vardiman JW (eds). Lyon, France: International Agency for Research on Cancer (IARC) Press, pp. 237-253, 2001.
27. Vassilakopoulos TP, Nadali G, Angelopoulou MK, Siakantaris MP, Dimopoulou MN, Kontopidou FN, Karkantaris C, Kokoris SI, Kyrtsonis MC, Tsaftaridis P, Pizzolo G and Pangalis GA: The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma. Haematologica 87: 701-708, 2002. (Pubitemid 34787140)
28. Tiemann M, Claviez A, Lüders H, Zimmermann M, Schellong G, Dörffel W and Parwaresch R: Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G1-phase. Mod Pathol 18: 1440-1447, 2005. (Pubitemid 41509398)
29. Montalbán C, García JF, Abraira V, González-Camacho L, Morente MM, Bello JL, Conde E, Cruz MA, García-Sanz R, García-Laraña J, Grande C, Llanos M, Martínez R, Flores E, Méndez M, Ponderós C, Rayón C, Sánchez-Godoy P, Zamora J and Piris MA; Spanish Hodgkin's Lymphoma Study Group: Influence of biologic markers on the outcome of Hogkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. J Clin Oncol 22: 1664-1673, 2004. (Pubitemid 41079805)
30. Heidebrecht HJ, Buck F, Endl E, Kruse ML, Adam-Klages S, Andersen K, Frahm SO, Schulte C, Wacker HH and Parwaresch R: Ki-Mcm6, a new monoclonal antibody specific to Mcm6: comparison of the distribution profile of Mcm6 and the Ki-67 antigen. Lab Invest 87: 1163-1165, 2001. (Pubitemid 32772076)
31. Schmidt MH, Broll R, Brach HP, Bögler O and Duchrow M: The proliferation marker pKi-67 organizes the nucleolus during the cell cycle depending on Ran and cyclin B. J Pathol 199: 18-27, 2003. (Pubitemid 36054725)
32. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000. (Pubitemid 30054364)
33. Tye BK: MCM proteins in DNA replication. Annu Rev Biochem 68: 649-686, 1999.
34. Saydam O, Senol O, Schaaij-Visser TB, Pham TV, Piersma SR, Stemmer-Rachamimov AO, Wurdinger T, Peerdeman SM and Jimenez CR: Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas. J Proteome Res 9: 485-494, 2010.
35. Wyrick JJ, Aparicio JG, Chen T, Barnett JD, Jennings EG, Young RA, Bell SP and Aparicio OM: Genome-wide distribution of ORC and MCM proteins in S. cerevisiae: high-resolution mapping of replication origins. Science 294: 2357-2360, 2001. (Pubitemid 33140560)
36. Nishihara K, Shomori K, Fujioka S, Tokuyasu N, Inaba A, Osaki M, Ogawa T and Ito H: Minichromosome maintenance protein 7 in colorectal cancer: implication of prognostic significance. Int J Oncol 33: 245-251, 2008.
37. Fujioka S, Shomori K, Nishihara K, Yamaga K, Nosaka K, Araki K, Haruki T, Taniguchi Y, Nakamura H and Ito H: Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): Prognostic implication. Lung Cancer 65: 223-229, 2009.